Table 4.
Most frequently reported (≥5 cases) serious adverse events (SAEs) during the 181-day postvaccination period (N=9143)
| SAE | Total n (%) | Time from previous vaccination dose to SAE (range in days) |
|---|---|---|
| At least one SAE | 411 (4.50) | |
| Pneumonia | 16 (0.17) | 30–178 |
| Lower respiratory tract infection | 13 (0.14) | 6–171 |
| Asthma | 13 (0.14) | 1–170 |
| Chest pain | 10 (0.11) | 3–180 |
| Urinary tract infection | 9 (0.10) | 14–147 |
| Chronic obstructive pulmonary disease | 8 (0.09) | 5–172 |
| Myocardial infarction | 7 (0.08) | 17–148 |
| Acute coronary syndrome | 6 (0.07) | 55–172 |
| Atrial fibrillation | 6 (0.07) | 1–157 |
| Abdominal pain | 6 (0.07) | <1–74 |
| Vomiting | 6 (0.07) | <1–176 |
| Transient ischaemic attack | 6 (0.07) | 2–173 |
| Cholecystitis | 5 (0.05) | 43–118 |
| Bronchopneumonia | 5 (0.05) | 1–103 |
| Sepsis | 5 (0.05) | 12–172 |
| Radius fracture | 5 (0.05) | 66–156 |
| Colon cancer | 5 (0.05) | 1–84 |
| Pulmonary embolism | 5 (0.05) | 11–157 |
n (%), number of participants reporting the event (percentage).